Free toolNo sign-up
Type a contract manufacturer, a site or an FEI number. See every FDA inspection outcome, warning letter and recall on file for it, by site, in seconds, with the industry's NAI, VAI and OAI split to compare against.
Try: , , ,
Markham, Canada · Drugs
FDA has published 1 inspection naming Everest Clinical Research.
Site: Markham, Canada (1, latest NAI)
100% of Everest Clinical Research's inspection closed with no action (NAI), against 44% of the 452 drug inspections FDA has posted with end dates since March 30, 2026 (44% NAI, 46% VAI, 10% OAI).
Name the CDMOs you compete with, the sites you run and the biotechs you sell to. One email when FDA inspects, writes to or recalls from any of them, with the record linked. A free account shows every source for the last 7 days. No card.
Start freeSponsors are checking you. A biotech's quality team looks up a manufacturer's FDA record before an audit, a quote and a tech transfer. This is the page they see, in the words FDA used.
Competitors change on inspection day. An OAI or a warning letter at another site is the week a sponsor starts looking for a second source. The record is public the day FDA posts it.
Your own sites, in one place. One name finds every site FDA lists under it, with the outcome of each visit, instead of one dashboard query per FEI.
FDA posts a classification after its review of the inspection is complete, often months after the inspection ended. Browse all inspection classifications, warning letters and recalls held, or look a company up in the company directory.
Type the contract manufacturer's name into the box above. The lookup searches the inspection classifications, warning letters and recalls FDA has published and shows every record that names the company, newest first, with the outcome of each inspection and a link to the record. It is free and needs no account. For history older than the records held here, FDA's Data Dashboard lists classified inspections back to 2009.
They are FDA's three inspection classifications. NAI, no action indicated: no objectionable conditions were found, or none that justify further action. VAI, voluntary action indicated: objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action. OAI, official action indicated: regulatory or administrative action is recommended, which can lead to a warning letter, an import alert or a consent decree.
From FDA's own publications: inspection classifications from the FDA Data Dashboard, warning letters from FDA's warning-letter listing, and recalls from FDA's weekly enforcement reports through openFDA. Each record on the result links to the agency's own page. Nothing is scraped from a company's website or typed in by hand.
FDA posts a classification only after its review of the inspection is complete, which is typically a few months after the inspection ended, and some inspections are never posted. The lookup shows what FDA has published, so an inspection that closed last month is usually not on the dashboard yet. A Form 483 is not published either; it reaches the public through a FOIA request, or when the company discloses it.
No. FDA does not publish most Form 483s. The lookup shows what is public: the inspection's classification, the CFR sections FDA cited where the dashboard lists them, and any warning letter that followed. A free account on the full product adds the cited sections on each inspection record.
Yes. Approve Suite Pro ($79 a month or $790 a year) lets you name the CDMOs, sites and biotechs you follow and emails you when FDA posts an inspection classification, warning letter or recall for any of them, with the record linked. A free account shows every record for the last 7 days. No card and no sales call.
No. An inspection outcome says what FDA found on one visit to one site, at one point in time. Every result links to FDA's own record, so you can read what it says.
Inspection classifications are from the FDA Data Dashboard; warning letters from FDA's listing; recalls from FDA's enforcement reports through openFDA. A record may have changed since it was read. The benchmark is a count of the records held, not a rating.
Approve Suite is not affiliated with FDA or with any company shown. See pricing and the FAQ for what the full product does.
